Effect of febuxostat on clinical outcomes in patients with hyperuricemia and cardiovascular disease
Masaaki Konishi,Sunao Kojima,Kazuaki Uchiyama,Naoto Yokota,Eiichi Tokutake,Yutaka Wakasa,Shinya Hiramitsu,Masako Waki,Hideaki Jinnouchi,Hirokazu Kakuda,Takahiro Hayashi,Naoki Kawai,Masahiro Sugawara,Hisao Mori,Kenichi Tsujita,Kunihiko Matsui,Ichiro Hisatome,Yusuke Ohya,Kazuo Kimura,Yoshihiko Saito,Hisao Ogawa,Febuxostat for Cerebral and Cardiorenovascular Events Prevention Study (FREED) investigators
DOI: https://doi.org/10.1016/j.ijcard.2021.11.076
2022-02-15
Abstract:Background: We previously reported on the FREED study, which found that febuxostat reduced the risk of adverse clinical outcome in patients with asymptomatic hyperuricemia without gout. We have now investigated outcomes in subgroups of FREED patients with and without a history of cardiovascular disease (CVD). Methods: We performed a post hoc subgroup analysis of 1070 patients randomized to the febuxostat or non-febuxostat group and followed for 36 months. Results: At baseline, 234 patients (21.9%) had a history of CVD, including 86 patients with stroke (36.8%), 90 with coronary artery disease (38.5%), 74 with heart failure (31.6%), and 25 with vascular disease (10.7%). The risk for the primary composite endpoint, i.e., cerebral, cardiovascular, and renal events and all deaths, was higher in patients with CVD than in those without CVD (34.2% vs 23.7%; p < 0.001). Treatment with febuxostat lowered rates of the primary composite endpoint in patients with CVD (hazard ratio [HR] 0.601, 95% CI 0.384 to 0.940, p = 0.026), and these effects were consistently observed in subgroups with and without CVD (p = 0.227 for treatment by subgroup interaction). Furthermore, in the subgroup with CVD, all-cause mortality was significantly lower in the febuxostat group than in the non-febuxostat group (HR 0.160, 95% CI 0.047 to 0.547, p = 0.004), with a significant subgroup interaction (p = 0.007 for treatment by subgroup interaction). Conclusions: In patients with asymptomatic hyperuricemia without gout, febuxostat reduces the risk of the composite of cerebral, cardiovascular, and renal events and death in the secondary prevention setting.